Mosaic ImmunoEngineering Submits Application for Nasdaq Uplisting

Author's Avatar
Jun 28, 2021

NOVATO, CA / ACCESSWIRE / June 28, 2021 / Mosaic ImmunoEngineering Inc. ("Mosaic" or the "Company"), (OTCQB:CPMV), a development-stage biotechnology company focused onimmunotherapies to treat and prevent cancer and infectious diseases through innate and adaptive immune activation, announced today that it has submitted its initial application to list the company's common stock on the Nasdaq Capital Market.